Podocalyxin (PCX) is a sialomucin that is most closely related to CD34 and endoglycan and is expressed by podocytes, hematopoietic progenitors, vascular endothelia, and a subset of neurons [13]. PCX is usually located on the apical cell membrane of podocytes and is shed into urine from injured podocytes [14]. Human urinary PCX (u-PCX) originates not from podocyte exosomes but from the tip vesiculation of glomerular podocyte microvilli [15]. Kanno et al. measured the levels of u-PCX in children with glomerular diseases such as IgAN and concluded that u-PCX was a useful biomarker for estimating the severity of active glomerular injury and could serve as a urinary index of acute extracapillary abnormalities in children [16]. Levels of u-PCX in adults with various forms of active glomerulonephritis were reported to be significantly higher than those in patients with chronic glomerulonephritis in long-term remission [17]. We used the Shigematsu classification to determine acute and chronic extracapillary abnormalities [18]. We found a positive correlation between levels of u-PCX and acute extracapillary abnormalities in adults with IgAN (Fig. 6.2) [12]. Conversely, levels of urinary protein excretion did not correlate with acute glomerular abnormalities. Acute extracapillary abnormalities can be followed by the detachment of podocytes and glomerular basement membrane (GBM) denudation, which are the initial steps in the development of glomerulosclerosis [19]. Possibly, u-PCX reflects acute extracapillary abnormalities and is an index of ongoing podocyte injury leading to glomerulosclerosis.

Several studies have shown that corticosteroid treatment decreases the levels of urinary protein excretion and improves renal outcomes in patients with IgAN [20–22]. Shoji et al. reported that early corticosteroid treatment for active and proliferative IgAN in adults was effective for reducing renal injury [23]. Immunosuppressive treatment, including corticosteroids, is recommended for crescentic IgAN with active glomerular inflammation [24]. These results suggest that the measurement of u-PCX may be a useful biomarker to determine the effectiveness of corticosteroid treatment.

Megalin is a large (600 kDa) glycoprotein that is a member of the low-density lipoprotein receptor family [25, 26]. It is highly expressed at the apical membranes of proximal tubular epithelial cells (PTECs) [27]. Megalin plays a central role in the endocytotic functions of PTECs [27]. Low-molecular-weight protein markers of PTEC injury, such as α1-microglobulin (α1-MG) and β2-microglobulin (β2-MG), are filtered by glomeruli and reabsorbed by PTECs via megalin [28, 29]. Megalin is detected in human urine, and increases in urinary megalin (uMegalin) excretion appear in microalbuminuric patients with type 1 diabetes [30–33]. The levels of uMegalin have been linked to the severity of diabetic nephropathy in type 2 diabetes [34].

To understand the relationship between the levels of uMegalin and renal histological findings in adult IgAN patients, we focused on uMegalin. The levels of uMegalin, α1-MG, β2-MG, and N-acetyl-β-D-glucosaminidase (NAG) are not correlated with tubular atrophy and interstitial fibrosis in the Oxford classification. Surprisingly, however, the levels of uMegalin are correlated with chronic extracapillary abnormalities, showing a distinctive significance compared to preexisting urinary biomarkers (β2-MG, α1-MG, NAG, and urinary total protein) (Fig. 6.3). In addition, the levels of uMegalin are correlated with mesangial hypercellularity in the Oxford classification. Megalin is localized in the brush border of proximal tubules, but not in the glomerulus in the human kidney [35, 36]. There are two proposed mechanisms for uMegalin levels that reflect glomerular abnormalities. The first theory is that glomerular abnormalities trigger PTEC dysfunction, leading to the excretion of megalin in the urine. Although it remains unclear how glomerular abnormalities lead to tubulointerstitial injury in IgAN, a possible pathogenetic mechanism is glomerulopodocytic-tubular communication [37]. The second theory involves the possibility that PTEC dysfunction aggravates chronic glomerular abnormalities. Selective PTEC injury reportedly drives the formation of interstitial fibrosis and potentially glomerulosclerosis [38]. The progression of PTEC injury may aggravate chronic extracapillary abnormalities and lead to glomerulosclerosis.

Supportive therapy with the cautious use of either angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) should be continued with IgAN patients in order to slow the process, although an eGFR that is persistently less than 30 mL/min/1.73 m² poses a substantial risk of progression to end-stage renal disease (ESRD) [39]. ACEI or ARB is effective for long-term renal survival of advanced IgAN patients whose histological findings contain chronic glomerular abnormalities [40]. In future studies, we aim to clarify whether uMegalin is a useful biomarker to determine the effectiveness of ACEI or ARB treatment. We also must examine the levels of uMegalin before and after the treatment of IgAN patients.

In our study, levels of uMegalin were associated with dialysis that required risk levels from the Clinical Guidelines for IgAN in Japan, third version [35, 41] (Fig. 6.4). The Oxford classification of IgAN identifies four pathologic abnormalities that independently determine the risk of developing progressive renal disease: mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, and tubular atrophy/interstitial fibrosis [7, 42]. Levels of uMegalin were correlated with only mesangial hypercellularity, according to the Oxford classification. Although levels of urinary β2-MG were correlated with segmental glomerulosclerosis, its urinary excretion offered no advantage over proteinuria to predict the prognosis in IgAN patients [43]. Thus, there is a possibility that uMegalin is an independent predictor of disease progression with IgAN. In future studies, it will be necessary to perform a longitudinal study to follow up with IgAN patients to determine whether uMegalin is a predictor.

The number of glomeruli obtained by renal biopsy was sometimes insufficient in order to evaluate the severity of glomerular changes. However, because u-PCX and uMegalin originate primarily from all nephrons in the kidney, the urinary biomarkers seem to reflect the histological findings of all nephrons. Urinary biomarkers might help us to speculate on the histological results of renal biopsy.

In conclusion, the biomarkers u-PCX and uMegalin have a potential role as an adjunct to the diagnosis of renal histology in IgAN patients.